Clinical Trials
210 trialsORCHID
Fudan University
Trastuzumab in Treating Women With Metastatic Breast Cancer
Centre Antoine Lacassagne
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
Dana-Farber Cancer Institute
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
University of Nebraska
IPATHER
SOLTI Breast Cancer Research Group
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer
Deraya University
Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa
Dana-Farber Cancer Institute
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
University of California, San Francisco
HIT
Institut Curie
SHIVA
Institut Curie
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Dana-Farber Cancer Institute
EMERALD
Japan Breast Cancer Research Group
PRECIOUS
Japan Breast Cancer Research Group
Tumor Markers for Efficacy of Dual-Target Therapy in HER2+ Breast Cancer
Shaanxi Provincial Cancer Hospital
Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy
Memorial Sloan Kettering Cancer Center
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Conversion Surgery After Target Therapy or Immunotherapy in Stage IV Gastric Cancer
Samsung Medical Center
Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer
M.D. Anderson Cancer Center
ADAPT; T-DM1
West German Study Group
ADAPT
West German Study Group
met-HEReMYTA
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
CRAFT: The NCT-PMO-1602 Phase II Trial
German Cancer Research Center
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
FLOT5
Krankenhaus Nordwest
NeoTOP
UNICANCER
ARRY-380 + Trastuzuamab for Breast w/ Brain Mets
Dana-Farber Cancer Institute
MIMOSA
The Netherlands Cancer Institute
Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer
Dana-Farber Cancer Institute
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Trastuzumab in Treating Older Women With Early-Stage Breast Cancer
Case Comprehensive Cancer Center
PATRICIA II
SOLTI Breast Cancer Research Group
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
University of California, Irvine
Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Fudan University
Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
NYU Langone Health
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
Hoosier Cancer Research Network
R2D2
Intergroupe Francophone de Cancerologie Thoracique
Intra-hepatic Chemotherapy in Patients With Liver Metastases From Breast Cancer and Limited Extrahepatic Disease
Herlev Hospital
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery
University of Nebraska
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
Columbia University
Clinical Efficacy of Trastuzumab in Combination With Capecitabine and Oxaliplatin for the Treatment of HER2-positive Advanced Gastric Cancer.
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review
Rawalpindi Medical College
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Yale University
Keyriched-1
West German Study Group
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
University of Washington